地西他滨联合小剂量阿糖胞苷治疗老年急性髓系白血病临床研究

Clinical study of decitabine combined with low-dose cytosine arabinoside in the treatment of acute myeloid leukemia in the elderly

目的评价老年急性髓系白血病给予地西他滨联合小剂量阿糖胞苷治疗的临床效果.方法45例老年急性髓系白血病患者,按2:1分为观察组(30例)与对照组(15例).对照组患者采用小剂量阿糖胞苷治疗,观察组患者采用地西他滨联合小剂量阿糖胞苷治疗.比较两组患者临床效果.结果观察组患者总缓解率为83.33%,对照组患者总缓解率为46.67%,观察组患者总缓解率高于对照组,差异有统计学意义(P<0.05).结论地西他滨联合小剂量阿糖胞苷治疗老年急性髓系白血病,治疗效果明显提高,患者均可耐受,值得进一步推广.

Objective To evaluate the clinical effect of decitabine combined with low-dose cytosine arabinoside in the treatment of acute myeloid leukemia in the elderly. Methods A total of 45 elderly patients with acute myeloid leukemia were divided into observation group (30 cases) and control group (15 cases) according to 2 : 1 ratio. The control group was treated with low-dose cytosine arabinoside, and the observation group was treated with decitabine combined with low-dose cytosine arabinoside. The clinical effect in two groups was compared. Results The observation group had total remission rate as 83.33%, and the control group had total remission rate as 46.67%. The observation group had higher total remission rate than the control group, and the difference was statistically significant (P<0.05). Conclusion Decitabine combined with low-dose cytosine arabinoside can improve the treatment effect of acute myeloid leukemia in the elderly, and patients are tolerable. It is worth further promotion.